Trial Profile
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sintilimab (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Acronyms ORIENT-1
- Sponsors Innovent Biologics
- 31 May 2020 Results updated safety and efficacy profile after long-term follow-up,presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results published in the Innovent Biologics Media Release.
- 31 May 2020 According to an Innovent Biologics media release, the company and Eli Lilly and Company jointly announced the results from this study at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO).